A BuiltForAI Property
Drug class profile · refreshed daily from federal data

Histamine-2 Receptor Antagonist

6 molecules in this class, $266.7M combined CY2024 Part D spend across 21.5M claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Histamine-2 Receptor Antagonist class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class
6tracked in Part D
CY24 Part D spend
$266.7Mcombined across class
Total Rx claims
21.5M7.2M unique beneficiaries
Generic mfrs (active)
52across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard
01
Famotidine
Brand: Pepcid · 21.4M Part D claims (CY24) · 7.1M beneficiaries · First FDA approval:
34 generic mfrs 0 plans require PA
Low NADAC$0.030
Avg plan cost$0.063
Part D spend $257.1M spread, current vs floor
Class share
96%
of class CY24 spend
View profile →
02
Cimetidine
151K Part D claims (CY24) · 46K beneficiaries · First FDA approval:
7 generic mfrs 0 plans require PA
Low NADAC$0.205
Avg plan cost$0.414
Part D spend $9.0M spread, current vs floor
Class share
3%
of class CY24 spend
View profile →
03
Nizatidine
7K Part D claims (CY24) · 2K beneficiaries · First FDA approval:
3 generic mfrs 0 plans require PA
Low NADAC$0.799
Avg plan cost$0.847
Part D spend $670367 spread, current vs floor
Class share
0%
of class CY24 spend
View profile →
04
Ibuprofen Famotidine
Part D claims (CY24) · First FDA approval:
Brand-only (no generics)
Low NADAC
Avg plan cost
Part D spend  
Class share
0%
of class CY24 spend
View profile →
05
Ibuprofen and Famotidine
Part D claims (CY24) · First FDA approval:
4 generic mfrs 6 plans require PA
Low NADAC$0.702
Avg plan cost$0.702
Part D spend spread, current vs floor
Class share
0%
of class CY24 spend
View profile →
06
Ranitidine
Part D claims (CY24) · First FDA approval:
4 generic mfrs 0 plans require PA
Low NADAC
Avg plan cost
Part D spend  
Class share
0%
of class CY24 spend
View profile →

Related questions.

Q&A librarySourced · reviewed quarterly
pricingWhat is NADAC?pricingIs NADAC the same as my PBM cost?pricingWhat is spread pricing?pricingWhat is a NADAC pass-through PBM contract?pricingWhat's the difference between AWP, MAC, and NADAC?pricingWhat is a dispensing fee in a PBM contract?
Browse all canonical questions →